Shiwei Cui

Dr. Shiwei Cui


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
YZYun Zhao
Yun Zhao
ZTZhuqi Tang
Zhuqi Tang
ASAiguo Shen
Aiguo Shen
TTTao Tao
Tao Tao
CWChunhua Wan
Chunhua Wan
DZDongmei Zhang
Dongmei Zhang
Protein tyrosine phosphatase 1B (PTP1B), which can directly dephosphorylate both the insulin receptor and insulin receptor substrate 1 (IRS-1), thereby terminating insulin signaling, reportedly plays an important role in insulin resistance. Accumulating evidence has demonstrated that O-GlcNAc modification regulates functions of several important components of insulin signal pathway. In this study, we identified that PTP1B is modified by O-GlcNAcylation at three O-GlcNAc sites (Ser104, Ser201, and Ser386). Palmitate acid (PA) impaired the insulin signaling, indicated by decreased phosphorylation of both serine/threonine-protein kinase B (Akt) and glycogen synthase kinase 3 beta (GSK3β) following insulin administration, and upregulated PTP1B O-GlcNAcylation in HepG2 cells. Compared with the wild-type, intervention PTP1B O-GlcNAcylation by site-directed gene mutation inhibited PTP1B phosphatase activity, resulted in a higher level of phosphorylated Akt and GSK3β, recovered insulin sensitivity, and improved lipid deposition in HepG2 cells. Taken together, our research showed that O-GlcNAcylation of PTP1B can influence insulin signal transduction by modulating its own phosphatase activity, which participates in the process of hepatic insulin resistance.

1 December 2015 in General and Comparative Endocrinology
Verified
Journal Article
Closed access
YZYun Zhao
Yun Zhao
ZTZhuqi Tang
Zhuqi Tang
XZXiaohui Zhu
Xiaohui Zhu
XWXueqin Wang
Xueqin Wang
CWCuifang Wang
Cuifang Wang
SCShiwei Cui
Shiwei Cui

YGYunjuan Gu
Yunjuan Gu
XHXuhong Hou
Xuhong Hou
YZYing Zheng
Ying Zheng
CWChunfang Wang
Chunfang Wang
LZLei Zhang
Lei Zhang
SCShiwei Cui
Shiwei Cui
Background: Evidence from epidemiologic investigation indicates that people with type 2 diabetes (T2DM) are at a significantly higher risk of many types of cancer and mortality. The aim of this study was to investigate the incidence and mortality risks of cancer in patients with T2DM compared with the general population in Shanghai, China. Methods: Based on the Shanghai Diabetes Registry (SDR) database linking to the Shanghai Cancer Registry and Surveillance System (SCRSS), a total of 12,276 T2DM patients without cancer were defined and followed up from 1 December 2001 to 31 July 2011. Standardized incidence ratio (SIR) and standardized mortality ratio (SMR) with 95% confidence interval (CI) were calculated using the whole gender and age-matched general population of Shanghai as a reference during the same period. Results: The overall cancer risk was found higher in both males and females T2DM patients, with the SIR of 3.14 (95% CI 2.73–3.56) and 4.29 (95% CI 3.64–4.94), respectively. The overall mortality risk of cancer also significantly increased with the SMR of 2.27 (95% CI 1.86–2.68) and 1.86 (95% CI 1.46–2.26), respectively. Pancreatic cancer was with the highest SIR and SMR in both genders. Conclusions: Compared with the general population, patients with T2DM were associated with higher incidence and mortality risks of cancer, especially pancreatic cancer.

1 January 2014
Verified
Journal Article
Closed access
YGYunjuan Gu
Yunjuan Gu
SCShiwei Cui
Shiwei Cui
HYHaoyong Yu
Haoyong Yu
CHCheng Hu
Cheng Hu
JLJunxi Lu
Junxi Lu
WJWeiping Jia
Weiping Jia